Abstract:At present, the drug treatment of Parkinson's disease cannot improve the damage of dopaminergic neurons. The protective mechanism of artemisinin which is economical and safe to protect dopaminergic neurons is discussed. Aims We performed cell and animal experiments to explore the therapeutic effect of artemisinin on Parkinson's disease (PD) and the TLR4/Myd88 signaling pathway. Methods C57 mice were randomly divided into the blank, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced and artemisinin‐treated groups. Clinical symptoms, the number of dopaminergic (DAergic) neurons in the substantia nigra, and microglial cell activation were compared among the three groups. Subsequently, BV‐2 cell activation and TLR4/Myd88 pathway component expression were compared among the blank, MPP+‐treated, artemisinin‐treated, and TLR4 activator‐treated groups. Results Behavioral symptoms were improved, the number of DAergic neurons in the substantia nigra of the midbrain was increased, and microglial cell activation was decreased in artemisinin‐treated MPTP‐induced PD model mice compared with control‐treated MPTP‐induced PD model mice (p

Artemisinin exerts a protective effect in the MPTP mouse model of Parkinson's disease by inhibiting microglial activation via the TLR4/Myd88/NF‐KB pathway